Summary
The obesity treatment market has shifted from a niche category to a major pharma growth engine, with revenues in the leading markets rising from about $16 billion in 2025 to a projected $80 billion by 2034 and potentially more than $100 billion by 2036.
Eli Lilly led the category in 2025, driven by MOUNJARO and ZEPBOUND; Lilly’s obesity and diabetes portfolio generated more than $36 billion in 2025 sales, and the company said those products helped power its record revenue growth.
Novo Nordisk’s WEGOVY and OZEMPIC remained major revenue drivers, but Lilly’s faster growth shifted the competitive balance in Lilly’s favor across the GLP-1 market.
The ...
